Imfinzi Approved in the US for Less-Frequent, Fixed-Dose Use

Article Link: Imfinzi Approved in the US for Less-Frequent, Fixed-Dose Use

20 November 2020 —  AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer…

Source: FDA New Drug Approvals